drugset / Trial / NCT04884984
Anti-CLL1 CAR T-cell Therapy in CLL1 Positive Relapsed/Refractory Acute Myeloid Leukemia (AML)
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label phase 1/2 study to evaluate the safety and efficacy of anti-CLL1 chimeric antigen receptor engineered T cell immunotherapy (CART) in the treatment of CLL1 positive relapsed or refractory acute myeloid leukemia.
Timeline
- Start
- 2017-07-01
- Primary completion
- 2022-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | anti-CLL1 CART | Cell therapy | 5e+06 cells/kg | Intravenous |
| Subject | anti-CLL1 CART | Cell therapy | 2e+07 cells/kg | Intravenous |